Zealand Pharma Shifts Resources to Obesity R&D
This briefing outlines corporate investment shifts toward metabolic treatments and clinical recommendations for obesity management, though it cannot establish specific recovery, individual variation, or treatment outcomes, and does not promise specific clinical results.








